Search Results for: Cancer

23406 interactions found:

Symbols Name 1 Name 2
Pathways 1
Pathways 2
Drugs 1
Drugs 2
Diseases 1
Diseases 2
CTNNB1 and FYN catenin (cadherin-associated protein), beta 1, 88kDa FYN proto-oncogene, Src family tyrosine kinase
  • APC truncation mutants have impaired AXIN binding
  • misspliced GSK3beta mutants stabilize beta-catenin
  • T41 mutants of beta-catenin aren't phosphorylated
  • TCF7L2 mutants don't bind CTBP
  • truncated APC mutants destabilize the destruction complex
  • Signaling by Wnt
  • binding of TCF/LEF:CTNNB1 to target gene promoters
  • deactivation of the beta-catenin transactivating complex
  • APC truncation mutants are not K63 polyubiquitinated
  • disassembly of the destruction complex and recruitment of AXIN to the membrane
  • S37 mutants of beta-catenin aren't phosphorylated
  • Degradation of beta-catenin by the destruction complex
  • AXIN mutants destabilize the destruction complex, activating WNT signaling
  • RNF mutants show enhanced WNT signaling and proliferation
  • S33 mutants of beta-catenin aren't phosphorylated
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • Innate Immune System
  • truncations of AMER1 destabilize the destruction complex
  • CDO in myogenesis
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • Cytosolic sensors of pathogen-associated DNA
  • formation of the beta-catenin:TCF transactivating complex
  • phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
  • AXIN missense mutants destabilize the destruction complex
  • S45 mutants of beta-catenin aren't phosphorylated
  • repression of WNT target genes
  • beta-catenin independent WNT signaling
  • deletions in the AMER1 gene destabilize the destruction complex
  • Ca2+ pathway
  • Myogenesis
  • AMER1 mutants destabilize the destruction complex
  • TCF dependent signaling in response to WNT
  • LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production
  • deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling
  • Signaling by WNT in cancer
  • Signaling by the B Cell Receptor (BCR)
  • Signaling by FGFR in disease
  • DCC mediated attractive signaling
  • Netrin mediated repulsion signals
  • Signaling by EGFRvIII in Cancer
  • Nef and signal transduction
  • Signaling by SCF-KIT
  • DAP12 signaling
  • Downstream signaling events of B Cell Receptor (BCR)
  • Regulation of KIT signaling
  • PI3K/AKT activation
  • PI-3K cascade
  • EPH-Ephrin signaling
  • Fcgamma receptor (FCGR) dependent phagocytosis
  • FCGR activation
  • Signaling by PDGF
  • DAP12 interactions
  • GAB1 signalosome
  • Host Interactions of HIV factors
  • CD28 co-stimulation
  • CD28 dependent PI3K/Akt signaling
  • The role of Nef in HIV-1 replication and disease pathogenesis
  • Signaling by ERBB4
  • Constitutive PI3K/AKT Signaling in Cancer
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • PI3K events in ERBB4 signaling
  • Signaling by ERBB2
  • Signaling by EGFR
  • Signaling by Interleukins
  • Signaling by VEGF
  • Downstream signal transduction
  • Sema3A PAK dependent Axon repulsion
  • Fc epsilon receptor (FCERI) signaling
  • Signaling by EGFR in Cancer
  • Nephrin interactions
  • SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion
  • CRMPs in Sema3A signaling
  • PI3K/AKT Signaling in Cancer
  • Platelet activation, signaling and aggregation
  • Interleukin-3, 5 and GM-CSF signaling
  • Adaptive Immune System
  • Platelet Adhesion to exposed collagen
  • Axon guidance
  • Costimulation by the CD28 family
  • PIP3 activates AKT signaling
  • HIV Infection
  • VEGFA-VEGFR2 Pathway
  • EPHB-mediated forward signaling
  • EPHA-mediated growth cone collapse
  • Ephrin signaling
  • EPH-ephrin mediated repulsion of cells
  • PI3K events in ERBB2 signaling
  • Regulation of signaling by CBL
  • Downstream signaling of activated FGFR
  • NCAM signaling for neurite out-growth
  • Netrin-1 signaling
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Innate Immune System
  • Signalling by NGF
  • Semaphorin interactions
  • CTLA4 inhibitory signaling
  • Cytokine Signaling in Immune system
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • NGF signalling via TRKA from the plasma membrane
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • PECAM1 interactions
  • CD28 dependent Vav1 pathway
  • Signaling by FGFR
  • Cell surface interactions at the vascular wall
  • GPVI-mediated activation cascade
  • Urea
  • Dasatinib
  • 1-Methoxy-2-[2-(2-Methoxy-Ethoxy]-Ethane
CTNNB1 and LEF1 catenin (cadherin-associated protein), beta 1, 88kDa lymphoid enhancer-binding factor 1
  • APC truncation mutants have impaired AXIN binding
  • misspliced GSK3beta mutants stabilize beta-catenin
  • T41 mutants of beta-catenin aren't phosphorylated
  • TCF7L2 mutants don't bind CTBP
  • truncated APC mutants destabilize the destruction complex
  • Signaling by Wnt
  • binding of TCF/LEF:CTNNB1 to target gene promoters
  • deactivation of the beta-catenin transactivating complex
  • APC truncation mutants are not K63 polyubiquitinated
  • disassembly of the destruction complex and recruitment of AXIN to the membrane
  • S37 mutants of beta-catenin aren't phosphorylated
  • Degradation of beta-catenin by the destruction complex
  • AXIN mutants destabilize the destruction complex, activating WNT signaling
  • RNF mutants show enhanced WNT signaling and proliferation
  • S33 mutants of beta-catenin aren't phosphorylated
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • Innate Immune System
  • truncations of AMER1 destabilize the destruction complex
  • CDO in myogenesis
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • Cytosolic sensors of pathogen-associated DNA
  • formation of the beta-catenin:TCF transactivating complex
  • phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
  • AXIN missense mutants destabilize the destruction complex
  • S45 mutants of beta-catenin aren't phosphorylated
  • repression of WNT target genes
  • beta-catenin independent WNT signaling
  • deletions in the AMER1 gene destabilize the destruction complex
  • Ca2+ pathway
  • Myogenesis
  • AMER1 mutants destabilize the destruction complex
  • TCF dependent signaling in response to WNT
  • LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production
  • deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling
  • Signaling by WNT in cancer
  • APC truncation mutants have impaired AXIN binding
  • misspliced GSK3beta mutants stabilize beta-catenin
  • T41 mutants of beta-catenin aren't phosphorylated
  • TCF7L2 mutants don't bind CTBP
  • truncated APC mutants destabilize the destruction complex
  • Signaling by Wnt
  • binding of TCF/LEF:CTNNB1 to target gene promoters
  • deactivation of the beta-catenin transactivating complex
  • APC truncation mutants are not K63 polyubiquitinated
  • Degradation of beta-catenin by the destruction complex
  • S37 mutants of beta-catenin aren't phosphorylated
  • S33 mutants of beta-catenin aren't phosphorylated
  • AXIN mutants destabilize the destruction complex, activating WNT signaling
  • RNF mutants show enhanced WNT signaling and proliferation
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • truncations of AMER1 destabilize the destruction complex
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • formation of the beta-catenin:TCF transactivating complex
  • phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
  • AXIN missense mutants destabilize the destruction complex
  • S45 mutants of beta-catenin aren't phosphorylated
  • repression of WNT target genes
  • beta-catenin independent WNT signaling
  • deletions in the AMER1 gene destabilize the destruction complex
  • Ca2+ pathway
  • TCF dependent signaling in response to WNT
  • AMER1 mutants destabilize the destruction complex
  • deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling
  • Signaling by WNT in cancer
  • Urea
CTNNB1 and PYGO1 catenin (cadherin-associated protein), beta 1, 88kDa pygopus family PHD finger 1
  • APC truncation mutants have impaired AXIN binding
  • misspliced GSK3beta mutants stabilize beta-catenin
  • T41 mutants of beta-catenin aren't phosphorylated
  • TCF7L2 mutants don't bind CTBP
  • truncated APC mutants destabilize the destruction complex
  • Signaling by Wnt
  • binding of TCF/LEF:CTNNB1 to target gene promoters
  • deactivation of the beta-catenin transactivating complex
  • APC truncation mutants are not K63 polyubiquitinated
  • disassembly of the destruction complex and recruitment of AXIN to the membrane
  • S37 mutants of beta-catenin aren't phosphorylated
  • Degradation of beta-catenin by the destruction complex
  • AXIN mutants destabilize the destruction complex, activating WNT signaling
  • RNF mutants show enhanced WNT signaling and proliferation
  • S33 mutants of beta-catenin aren't phosphorylated
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • Innate Immune System
  • truncations of AMER1 destabilize the destruction complex
  • CDO in myogenesis
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • Cytosolic sensors of pathogen-associated DNA
  • formation of the beta-catenin:TCF transactivating complex
  • phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
  • AXIN missense mutants destabilize the destruction complex
  • S45 mutants of beta-catenin aren't phosphorylated
  • repression of WNT target genes
  • beta-catenin independent WNT signaling
  • deletions in the AMER1 gene destabilize the destruction complex
  • Ca2+ pathway
  • Myogenesis
  • AMER1 mutants destabilize the destruction complex
  • TCF dependent signaling in response to WNT
  • LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production
  • deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling
  • Signaling by WNT in cancer
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • TCF dependent signaling in response to WNT
  • RNF mutants show enhanced WNT signaling and proliferation
  • formation of the beta-catenin:TCF transactivating complex
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • Signaling by Wnt
  • Signaling by WNT in cancer
  • deactivation of the beta-catenin transactivating complex
  • Urea
CTNNB1 and TCF7L1 catenin (cadherin-associated protein), beta 1, 88kDa transcription factor 7-like 1 (T-cell specific, HMG-box)
  • APC truncation mutants have impaired AXIN binding
  • misspliced GSK3beta mutants stabilize beta-catenin
  • T41 mutants of beta-catenin aren't phosphorylated
  • TCF7L2 mutants don't bind CTBP
  • truncated APC mutants destabilize the destruction complex
  • Signaling by Wnt
  • binding of TCF/LEF:CTNNB1 to target gene promoters
  • deactivation of the beta-catenin transactivating complex
  • APC truncation mutants are not K63 polyubiquitinated
  • disassembly of the destruction complex and recruitment of AXIN to the membrane
  • S37 mutants of beta-catenin aren't phosphorylated
  • Degradation of beta-catenin by the destruction complex
  • AXIN mutants destabilize the destruction complex, activating WNT signaling
  • RNF mutants show enhanced WNT signaling and proliferation
  • S33 mutants of beta-catenin aren't phosphorylated
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • Innate Immune System
  • truncations of AMER1 destabilize the destruction complex
  • CDO in myogenesis
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • Cytosolic sensors of pathogen-associated DNA
  • formation of the beta-catenin:TCF transactivating complex
  • phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
  • AXIN missense mutants destabilize the destruction complex
  • S45 mutants of beta-catenin aren't phosphorylated
  • repression of WNT target genes
  • beta-catenin independent WNT signaling
  • deletions in the AMER1 gene destabilize the destruction complex
  • Ca2+ pathway
  • Myogenesis
  • AMER1 mutants destabilize the destruction complex
  • TCF dependent signaling in response to WNT
  • LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production
  • deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling
  • Signaling by WNT in cancer
  • APC truncation mutants have impaired AXIN binding
  • misspliced GSK3beta mutants stabilize beta-catenin
  • T41 mutants of beta-catenin aren't phosphorylated
  • TCF7L2 mutants don't bind CTBP
  • truncated APC mutants destabilize the destruction complex
  • Signaling by Wnt
  • binding of TCF/LEF:CTNNB1 to target gene promoters
  • deactivation of the beta-catenin transactivating complex
  • APC truncation mutants are not K63 polyubiquitinated
  • Degradation of beta-catenin by the destruction complex
  • S37 mutants of beta-catenin aren't phosphorylated
  • S33 mutants of beta-catenin aren't phosphorylated
  • AXIN mutants destabilize the destruction complex, activating WNT signaling
  • RNF mutants show enhanced WNT signaling and proliferation
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • truncations of AMER1 destabilize the destruction complex
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • formation of the beta-catenin:TCF transactivating complex
  • phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
  • AXIN missense mutants destabilize the destruction complex
  • S45 mutants of beta-catenin aren't phosphorylated
  • repression of WNT target genes
  • beta-catenin independent WNT signaling
  • deletions in the AMER1 gene destabilize the destruction complex
  • Ca2+ pathway
  • TCF dependent signaling in response to WNT
  • AMER1 mutants destabilize the destruction complex
  • deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling
  • Signaling by WNT in cancer
  • Urea
CTNNB1 and EP300 catenin (cadherin-associated protein), beta 1, 88kDa E1A binding protein p300
  • APC truncation mutants have impaired AXIN binding
  • misspliced GSK3beta mutants stabilize beta-catenin
  • T41 mutants of beta-catenin aren't phosphorylated
  • TCF7L2 mutants don't bind CTBP
  • truncated APC mutants destabilize the destruction complex
  • Signaling by Wnt
  • binding of TCF/LEF:CTNNB1 to target gene promoters
  • deactivation of the beta-catenin transactivating complex
  • APC truncation mutants are not K63 polyubiquitinated
  • disassembly of the destruction complex and recruitment of AXIN to the membrane
  • S37 mutants of beta-catenin aren't phosphorylated
  • Degradation of beta-catenin by the destruction complex
  • AXIN mutants destabilize the destruction complex, activating WNT signaling
  • RNF mutants show enhanced WNT signaling and proliferation
  • S33 mutants of beta-catenin aren't phosphorylated
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • Innate Immune System
  • truncations of AMER1 destabilize the destruction complex
  • CDO in myogenesis
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • Cytosolic sensors of pathogen-associated DNA
  • formation of the beta-catenin:TCF transactivating complex
  • phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
  • AXIN missense mutants destabilize the destruction complex
  • S45 mutants of beta-catenin aren't phosphorylated
  • repression of WNT target genes
  • beta-catenin independent WNT signaling
  • deletions in the AMER1 gene destabilize the destruction complex
  • Ca2+ pathway
  • Myogenesis
  • AMER1 mutants destabilize the destruction complex
  • TCF dependent signaling in response to WNT
  • LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production
  • deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling
  • Signaling by WNT in cancer
  • Signaling by NOTCH1 HD Domain Mutants in Cancer
  • Metabolism of lipids and lipoproteins
  • Signaling by Wnt
  • NOTCH2 intracellular domain regulates transcription
  • Regulation of gene expression by Hypoxia-inducible Factor
  • Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant
  • Signaling by NOTCH2
  • Pre-NOTCH Transcription and Translation
  • RNF mutants show enhanced WNT signaling and proliferation
  • Signaling by NOTCH1 in Cancer
  • Chromatin organization
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • Signaling by NOTCH
  • formation of the beta-catenin:TCF transactivating complex
  • Factors involved in megakaryocyte development and platelet production
  • Chromatin modifying enzymes
  • LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production
  • Signaling by NOTCH1 PEST Domain Mutants in Cancer
  • Mitotic G2-G2/M phases
  • Constitutive Signaling by NOTCH1 PEST Domain Mutants
  • PPARA activates gene expression
  • Cellular response to hypoxia
  • Regulation of Hypoxia-inducible Factor (HIF) by oxygen
  • Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer
  • Attenuation phase
  • G2/M Transition
  • HATs acetylate histones
  • RORA activates circadian gene expression
  • HSF1-dependent transactivation
  • TRAF3-dependent IRF activation pathway
  • Signaling by NOTCH1
  • Transcriptional regulation of white adipocyte differentiation
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • Pre-NOTCH Expression and Processing
  • Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
  • FBXW7 Mutants and NOTCH1 in Cancer
  • Innate Immune System
  • Fatty acid, triacylglycerol, and ketone body metabolism
  • Cytosolic sensors of pathogen-associated DNA
  • Cellular response to heat stress
  • REV-ERBA represses gene expression
  • Cell Cycle, Mitotic
  • RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways
  • NOTCH1 Intracellular Domain Regulates Transcription
  • TCF dependent signaling in response to WNT
  • TRAF6 mediated IRF7 activation
  • Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
  • Signaling by WNT in cancer
  • BMAL1:CLOCK,NPAS2 activates circadian gene expression
  • Polo-like kinase mediated events
  • Urea
CTNNB1 and SMAD3 catenin (cadherin-associated protein), beta 1, 88kDa SMAD family member 3
  • APC truncation mutants have impaired AXIN binding
  • misspliced GSK3beta mutants stabilize beta-catenin
  • T41 mutants of beta-catenin aren't phosphorylated
  • TCF7L2 mutants don't bind CTBP
  • truncated APC mutants destabilize the destruction complex
  • Signaling by Wnt
  • binding of TCF/LEF:CTNNB1 to target gene promoters
  • deactivation of the beta-catenin transactivating complex
  • APC truncation mutants are not K63 polyubiquitinated
  • disassembly of the destruction complex and recruitment of AXIN to the membrane
  • S37 mutants of beta-catenin aren't phosphorylated
  • Degradation of beta-catenin by the destruction complex
  • AXIN mutants destabilize the destruction complex, activating WNT signaling
  • RNF mutants show enhanced WNT signaling and proliferation
  • S33 mutants of beta-catenin aren't phosphorylated
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • Innate Immune System
  • truncations of AMER1 destabilize the destruction complex
  • CDO in myogenesis
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • Cytosolic sensors of pathogen-associated DNA
  • formation of the beta-catenin:TCF transactivating complex
  • phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
  • AXIN missense mutants destabilize the destruction complex
  • S45 mutants of beta-catenin aren't phosphorylated
  • repression of WNT target genes
  • beta-catenin independent WNT signaling
  • deletions in the AMER1 gene destabilize the destruction complex
  • Ca2+ pathway
  • Myogenesis
  • AMER1 mutants destabilize the destruction complex
  • TCF dependent signaling in response to WNT
  • LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production
  • deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling
  • Signaling by WNT in cancer
  • Loss of Function of TGFBR2 in Cancer
  • SMAD2/3 MH2 Domain Mutants in Cancer
  • Downregulation of TGF-beta receptor signaling
  • TGF-beta receptor signaling activates SMADs
  • TGFBR1 LBD Mutants in Cancer
  • Downregulation of SMAD2/3:SMAD4 transcriptional activity
  • SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
  • Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer
  • Generic Transcription Pathway
  • Signaling by NODAL
  • TGFBR2 MSI Frameshift Mutants in Cancer
  • SMAD2/3 Phosphorylation Motif Mutants in Cancer
  • Loss of Function of SMAD2/3 in Cancer
  • Signaling by Activin
  • TGFBR2 Kinase Domain Mutants in Cancer
  • Loss of Function of SMAD4 in Cancer
  • TGFBR1 KD Mutants in Cancer
  • Loss of Function of TGFBR1 in Cancer
  • Signaling by TGF-beta Receptor Complex in Cancer
  • Signaling by TGF-beta Receptor Complex
  • SMAD4 MH2 Domain Mutants in Cancer
  • Urea
DAB2 and SMAD2 Dab, mitogen-responsive phosphoprotein, homolog 2 (Drosophila) SMAD family member 2
  • Formation of annular gap junctions
  • Gap junction degradation
  • Gap junction trafficking and regulation
  • Gap junction trafficking
  • Loss of Function of TGFBR2 in Cancer
  • SMAD2/3 MH2 Domain Mutants in Cancer
  • Downregulation of TGF-beta receptor signaling
  • TGF-beta receptor signaling activates SMADs
  • TGFBR1 LBD Mutants in Cancer
  • Downregulation of SMAD2/3:SMAD4 transcriptional activity
  • SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
  • Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer
  • Generic Transcription Pathway
  • Signaling by NODAL
  • TGFBR2 MSI Frameshift Mutants in Cancer
  • SMAD2/3 Phosphorylation Motif Mutants in Cancer
  • Loss of Function of SMAD2/3 in Cancer
  • Signaling by Activin
  • TGFBR2 Kinase Domain Mutants in Cancer
  • Loss of Function of SMAD4 in Cancer
  • TGFBR1 KD Mutants in Cancer
  • Loss of Function of TGFBR1 in Cancer
  • Signaling by TGF-beta Receptor Complex in Cancer
  • Signaling by TGF-beta Receptor Complex
  • SMAD4 MH2 Domain Mutants in Cancer
DAPK1 and MIB1 death-associated protein kinase 1 mindbomb E3 ubiquitin protein ligase 1
  • Programmed Cell Death
  • Role of DCC in regulating apoptosis
  • Extrinsic Pathway
  • Signaling by NOTCH1 HD Domain Mutants in Cancer
  • Constitutive Signaling by NOTCH1 HD Domain Mutants
  • Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer
  • Signaling by NOTCH
  • NOTCH2 Activation and Transmission of Signal to the Nucleus
  • Activated NOTCH1 Transmits Signal to the Nucleus
  • Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant
  • Signaling by NOTCH2
  • Signaling by NOTCH1
  • Signaling by NOTCH1 PEST Domain Mutants in Cancer
  • Signaling by NOTCH1 in Cancer
  • Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
  • Constitutive Signaling by NOTCH1 PEST Domain Mutants
  • FBXW7 Mutants and NOTCH1 in Cancer
  • 5,6-Dihydro-Benzo[H]Cinnolin-3-Ylamine
  • Phosphoaminophosphonic Acid-Adenylate Ester
  • 6-(3-AMINOPROPYL)-4,9-DIMETHYLPYRROLO[3,4-C]CARBAZOLE-1,3(2H,6H)-DIONE
DAPK1 and MAPK1 death-associated protein kinase 1 mitogen-activated protein kinase 1
  • Programmed Cell Death
  • Role of DCC in regulating apoptosis
  • Extrinsic Pathway
  • phospho-PLA2 pathway
  • Ca-dependent events
  • Signaling by FGFR in disease
  • Cellular Senescence
  • ERKs are inactivated
  • CREB phosphorylation through the activation of Ras
  • Signaling by EGFRvIII in Cancer
  • Toll Like Receptor TLR1:TLR2 Cascade
  • Toll Like Receptor 5 (TLR5) Cascade
  • Gastrin-CREB signalling pathway via PKC and MAPK
  • MyD88 dependent cascade initiated on endosome
  • SOS-mediated signalling
  • Fcgamma receptor (FCGR) dependent phagocytosis
  • SHC-mediated signalling
  • Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
  • Regulation of actin dynamics for phagocytic cup formation
  • TRIF-mediated TLR3/TLR4 signaling
  • Senescence-Associated Secretory Phenotype (SASP)
  • Signaling by VEGF
  • Signalling to RAS
  • Downstream signal transduction
  • Toll Like Receptor 3 (TLR3) Cascade
  • Interleukin-2 signaling
  • Platelet activation, signaling and aggregation
  • Frs2-mediated activation
  • Transmission across Chemical Synapses
  • Axon guidance
  • IRS-mediated signalling
  • L1CAM interactions
  • Oncogene Induced Senescence
  • VEGFA-VEGFR2 Pathway
  • Activated TLR4 signalling
  • VEGFR2 mediated cell proliferation
  • GRB2 events in ERBB2 signaling
  • RSK activation
  • Activation of NMDA receptor upon glutamate binding and postsynaptic events
  • TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
  • MyD88:Mal cascade initiated on plasma membrane
  • NCAM signaling for neurite out-growth
  • Signalling to p38 via RIT and RIN
  • RAF/MAP kinase cascade
  • Innate Immune System
  • Signaling by Insulin receptor
  • ERKs are inactivated
  • Signal transduction by L1
  • Insulin receptor signalling cascade
  • PLC beta mediated events
  • IRS-related events
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • SHC-related events
  • G-protein mediated events
  • Signaling by FGFR
  • Thrombin signalling through proteinase activated receptors (PARs)
  • ARMS-mediated activation
  • Toll-Like Receptors Cascades
  • Toll Like Receptor 10 (TLR10) Cascade
  • Signal attenuation
  • Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
  • ERK/MAPK targets
  • MAPK targets/ Nuclear events mediated by MAP kinases
  • Signaling by GPCR
  • Mitotic Prophase
  • Golgi Cisternae Pericentriolar Stack Reorganization
  • FCERI mediated MAPK activation
  • Signaling by SCF-KIT
  • SHC1 events in ERBB2 signaling
  • DAP12 signaling
  • Toll Like Receptor 9 (TLR9) Cascade
  • ERK/MAPK targets
  • Negative regulation of FGFR signaling
  • Signaling by PDGF
  • DAP12 interactions
  • Opioid Signalling
  • SHC-related events triggered by IGF1R
  • GRB2 events in EGFR signaling
  • Signaling by ERBB4
  • Toll Like Receptor 2 (TLR2) Cascade
  • Signaling by ERBB2
  • Signaling by EGFR
  • Signaling by Interleukins
  • SHC1 events in ERBB4 signaling
  • Toll Like Receptor 4 (TLR4) Cascade
  • Fc epsilon receptor (FCERI) signaling
  • Signaling by EGFR in Cancer
  • Signaling by Leptin
  • Growth hormone receptor signaling
  • Signalling to ERKs
  • Prolonged ERK activation events
  • ERK activation
  • Toll Like Receptor 7/8 (TLR7/8) Cascade
  • IGF1R signaling cascade
  • Recycling pathway of L1
  • M Phase
  • Toll Like Receptor TLR6:TLR2 Cascade
  • IRS-related events triggered by IGF1R
  • Activation of the AP-1 family of transcription factors
  • MyD88 cascade initiated on plasma membrane
  • ERK activation
  • Downstream signaling of activated FGFR
  • Advanced glycosylation endproduct receptor signaling
  • Post NMDA receptor activation events
  • Signalling by NGF
  • SOS-mediated signalling
  • MAP kinase activation in TLR cascade
  • SHC-mediated signalling
  • Cytokine Signaling in Immune system
  • Cellular response to heat stress
  • Regulation of HSF1-mediated heat shock response
  • NGF signalling via TRKA from the plasma membrane
  • MyD88-independent cascade
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Cell Cycle, Mitotic
  • ERK2 activation
  • SHC1 events in EGFR signaling
  • FRS2-mediated cascade
  • IRS-mediated signalling
  • Oxidative Stress Induced Senescence
  • ERK2 activation
  • Nuclear Events (kinase and transcription factor activation)
  • 5,6-Dihydro-Benzo[H]Cinnolin-3-Ylamine
  • Phosphoaminophosphonic Acid-Adenylate Ester
  • 6-(3-AMINOPROPYL)-4,9-DIMETHYLPYRROLO[3,4-C]CARBAZOLE-1,3(2H,6H)-DIONE
  • Isoproterenol
  • Arsenic trioxide
  • Olomoucine
  • Phosphonothreonine
  • Purvalanol
  • SB220025
  • N,N-DIMETHYL-4-(4-PHENYL-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE
  • N-BENZYL-4-[4-(3-CHLOROPHENYL)-1H-PYRAZOL-3-YL]-1H-PYRROLE-2-CARBOXAMIDE
  • (S)-N-(1-(3-CHLORO-4-FLUOROPHENYL)-2-HYDROXYETHYL)-4-(4-(3-CHLOROPHENYL)-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE
  • (3R,5Z,8S,9S,11E)-8,9,16-TRIHYDROXY-14-METHOXY-3-METHYL-3,4,9,10-TETRAHYDRO-1H-2-BENZOXACYCLOTETRADECINE-1,7(8H)-DIONE
  • 5-(2-PHENYLPYRAZOLO[1,5-A]PYRIDIN-3-YL)-1H-PYRAZOLO[3,4-C]PYRIDAZIN-3-AMINE
  • (1aR,8S,13S,14S,15aR)-5,13,14-trihydroxy-3-methoxy-8-methyl-8,9,13,14,15,15a-hexahydro-6H-oxireno[k][2]benzoxacyclotetradecine-6,12(1aH)-dione
  • [4-({5-(AMINOCARBONYL)-4-[(3-METHYLPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENYL]ACETIC ACID
  • 4-[5-(4-FLUORO-PHENYL)-2-(4-METHANESULFINYL-PHENYL)-3H-IMIDAZOL-4-YL]-PYRIDINE
DAPK1 and MAPK3 death-associated protein kinase 1 mitogen-activated protein kinase 3
  • Programmed Cell Death
  • Role of DCC in regulating apoptosis
  • Extrinsic Pathway
  • Signaling by FGFR in disease
  • RNA Polymerase I, RNA Polymerase III, and Mitochondrial Transcription
  • Cellular Senescence
  • ERKs are inactivated
  • Signaling by EGFRvIII in Cancer
  • Toll Like Receptor TLR1:TLR2 Cascade
  • Toll Like Receptor 5 (TLR5) Cascade
  • Gastrin-CREB signalling pathway via PKC and MAPK
  • MyD88 dependent cascade initiated on endosome
  • SOS-mediated signalling
  • Fcgamma receptor (FCGR) dependent phagocytosis
  • SHC-mediated signalling
  • Regulation of actin dynamics for phagocytic cup formation
  • TRIF-mediated TLR3/TLR4 signaling
  • ERK1 activation
  • Senescence-Associated Secretory Phenotype (SASP)
  • ERK1 activation
  • Signaling by VEGF
  • Downstream signal transduction
  • Toll Like Receptor 3 (TLR3) Cascade
  • Signalling to RAS
  • Interleukin-2 signaling
  • Platelet activation, signaling and aggregation
  • Frs2-mediated activation
  • Axon guidance
  • IRS-mediated signalling
  • L1CAM interactions
  • Oncogene Induced Senescence
  • VEGFA-VEGFR2 Pathway
  • Activated TLR4 signalling
  • VEGFR2 mediated cell proliferation
  • GRB2 events in ERBB2 signaling
  • TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
  • MyD88:Mal cascade initiated on plasma membrane
  • NCAM signaling for neurite out-growth
  • RAF/MAP kinase cascade
  • Signalling to p38 via RIT and RIN
  • Innate Immune System
  • Signaling by Insulin receptor
  • ERKs are inactivated
  • Signal transduction by L1
  • Insulin receptor signalling cascade
  • ISG15 antiviral mechanism
  • Interferon Signaling
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • IRS-related events
  • SHC-related events
  • Signaling by FGFR
  • Thrombin signalling through proteinase activated receptors (PARs)
  • ARMS-mediated activation
  • Toll-Like Receptors Cascades
  • Toll Like Receptor 10 (TLR10) Cascade
  • Signal attenuation
  • Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
  • ERK/MAPK targets
  • MAPK targets/ Nuclear events mediated by MAP kinases
  • Signaling by GPCR
  • FCERI mediated MAPK activation
  • SHC1 events in ERBB2 signaling
  • Signaling by SCF-KIT
  • DAP12 signaling
  • Toll Like Receptor 9 (TLR9) Cascade
  • ERK/MAPK targets
  • Negative regulation of FGFR signaling
  • Signaling by PDGF
  • DAP12 interactions
  • SHC-related events triggered by IGF1R
  • GRB2 events in EGFR signaling
  • Signaling by ERBB4
  • Antiviral mechanism by IFN-stimulated genes
  • Toll Like Receptor 2 (TLR2) Cascade
  • Signaling by ERBB2
  • Signaling by EGFR
  • Signaling by Interleukins
  • SHC1 events in ERBB4 signaling
  • Toll Like Receptor 4 (TLR4) Cascade
  • Fc epsilon receptor (FCERI) signaling
  • Signaling by EGFR in Cancer
  • Growth hormone receptor signaling
  • Signaling by Leptin
  • Signalling to ERKs
  • Prolonged ERK activation events
  • ERK activation
  • Toll Like Receptor 7/8 (TLR7/8) Cascade
  • RNA Polymerase I Promoter Clearance
  • IGF1R signaling cascade
  • Toll Like Receptor TLR6:TLR2 Cascade
  • IRS-related events triggered by IGF1R
  • Activation of the AP-1 family of transcription factors
  • MyD88 cascade initiated on plasma membrane
  • ERK activation
  • Downstream signaling of activated FGFR
  • Advanced glycosylation endproduct receptor signaling
  • Signalling by NGF
  • SOS-mediated signalling
  • MAP kinase activation in TLR cascade
  • RNA Polymerase I Transcription
  • SHC-mediated signalling
  • Cytokine Signaling in Immune system
  • Cellular response to heat stress
  • Regulation of HSF1-mediated heat shock response
  • NGF signalling via TRKA from the plasma membrane
  • MyD88-independent cascade
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • SHC1 events in EGFR signaling
  • FRS2-mediated cascade
  • IRS-mediated signalling
  • Oxidative Stress Induced Senescence
  • RNA Polymerase I Promoter Opening
  • Nuclear Events (kinase and transcription factor activation)
  • 5,6-Dihydro-Benzo[H]Cinnolin-3-Ylamine
  • Phosphoaminophosphonic Acid-Adenylate Ester
  • 6-(3-AMINOPROPYL)-4,9-DIMETHYLPYRROLO[3,4-C]CARBAZOLE-1,3(2H,6H)-DIONE
  • Sulindac
  • Arsenic trioxide
  • Purvalanol
  • 5-iodotubercidin
DAPK1 and YWHAB death-associated protein kinase 1 tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, beta
  • Programmed Cell Death
  • Role of DCC in regulating apoptosis
  • Extrinsic Pathway
  • Signaling by GPCR
  • Signaling by FGFR in disease
  • Activation of BH3-only proteins
  • MEK activation
  • FCERI mediated MAPK activation
  • Signaling by EGFRvIII in Cancer
  • SHC1 events in ERBB2 signaling
  • Signaling by SCF-KIT
  • DAP12 signaling
  • Rap1 signalling
  • Gastrin-CREB signalling pathway via PKC and MAPK
  • SOS-mediated signalling
  • SHC-mediated signalling
  • Signaling by PDGF
  • Regulation of mRNA stability by proteins that bind AU-rich elements
  • DAP12 interactions
  • SHC-related events triggered by IGF1R
  • GRB2 events in EGFR signaling
  • Signaling by ERBB4
  • Signaling by ERBB2
  • Activation of BAD and translocation to mitochondria
  • Signaling by EGFR
  • Signaling by Interleukins
  • SHC1 events in ERBB4 signaling
  • Signaling by VEGF
  • Signalling to RAS
  • Downstream signal transduction
  • Fc epsilon receptor (FCERI) signaling
  • Signaling by EGFR in Cancer
  • Interleukin-2 signaling
  • Frs2-mediated activation
  • Adaptive Immune System
  • Signaling by Leptin
  • Signalling to ERKs
  • Prolonged ERK activation events
  • Axon guidance
  • IRS-mediated signalling
  • Translocation of GLUT4 to the plasma membrane
  • IGF1R signaling cascade
  • VEGFA-VEGFR2 Pathway
  • IRS-related events triggered by IGF1R
  • GRB2 events in ERBB2 signaling
  • VEGFR2 mediated cell proliferation
  • RAF phosphorylates MEK
  • Downstream signaling of activated FGFR
  • Programmed Cell Death
  • NCAM signaling for neurite out-growth
  • RAF/MAP kinase cascade
  • Signalling to p38 via RIT and RIN
  • Intrinsic Pathway for Apoptosis
  • Butyrate Response Factor 1 (BRF1) destabilizes mRNA
  • Innate Immune System
  • Signaling by Insulin receptor
  • Signalling by NGF
  • Insulin receptor signalling cascade
  • SOS-mediated signalling
  • SHC-mediated signalling
  • Cytokine Signaling in Immune system
  • IRS-related events
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • Tristetraprolin (TTP) destabilizes mRNA
  • NGF signalling via TRKA from the plasma membrane
  • SHC-related events
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Signaling by FGFR
  • ARMS-mediated activation
  • Signaling by Hippo
  • RAF activation
  • SHC1 events in EGFR signaling
  • IRS-mediated signalling
  • FRS2-mediated cascade
  • Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
  • 5,6-Dihydro-Benzo[H]Cinnolin-3-Ylamine
  • Phosphoaminophosphonic Acid-Adenylate Ester
  • 6-(3-AMINOPROPYL)-4,9-DIMETHYLPYRROLO[3,4-C]CARBAZOLE-1,3(2H,6H)-DIONE
DAXX and TGFBR2 death-domain associated protein transforming growth factor, beta receptor II (70/80kDa)
  • Loss of Function of TGFBR2 in Cancer
  • TGFBR2 MSI Frameshift Mutants in Cancer
  • TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
  • SMAD2/3 Phosphorylation Motif Mutants in Cancer
  • Loss of Function of SMAD2/3 in Cancer
  • TGFBR2 Kinase Domain Mutants in Cancer
  • Downregulation of TGF-beta receptor signaling
  • SMAD2/3 MH2 Domain Mutants in Cancer
  • Loss of Function of SMAD4 in Cancer
  • TGFBR1 KD Mutants in Cancer
  • TGF-beta receptor signaling activates SMADs
  • TGFBR1 LBD Mutants in Cancer
  • Loss of Function of TGFBR1 in Cancer
  • Signaling by TGF-beta Receptor Complex in Cancer
  • Signaling by TGF-beta Receptor Complex
  • SMAD4 MH2 Domain Mutants in Cancer
  • Glycerol
DCC and SIAH2 DCC netrin 1 receptor siah E3 ubiquitin protein ligase 2
  • DSCAM interactions
  • Axon guidance
  • Role of second messengers in netrin-1 signaling
  • DCC mediated attractive signaling
  • Programmed Cell Death
  • Netrin mediated repulsion signals
  • Netrin-1 signaling
  • Role of DCC in regulating apoptosis
  • Extrinsic Pathway
  • Axon guidance
  • Netrin-1 signaling
DCC and NTN1 DCC netrin 1 receptor netrin 1
  • DSCAM interactions
  • Axon guidance
  • Role of second messengers in netrin-1 signaling
  • DCC mediated attractive signaling
  • Programmed Cell Death
  • Netrin mediated repulsion signals
  • Netrin-1 signaling
  • Role of DCC in regulating apoptosis
  • Extrinsic Pathway
  • DSCAM interactions
  • Axon guidance
  • Role of second messengers in netrin-1 signaling
  • DCC mediated attractive signaling
  • Netrin mediated repulsion signals
  • Netrin-1 signaling
DCC and MAPK3 DCC netrin 1 receptor mitogen-activated protein kinase 3
  • DSCAM interactions
  • Axon guidance
  • Role of second messengers in netrin-1 signaling
  • DCC mediated attractive signaling
  • Programmed Cell Death
  • Netrin mediated repulsion signals
  • Netrin-1 signaling
  • Role of DCC in regulating apoptosis
  • Extrinsic Pathway
  • Signaling by FGFR in disease
  • RNA Polymerase I, RNA Polymerase III, and Mitochondrial Transcription
  • Cellular Senescence
  • ERKs are inactivated
  • Signaling by EGFRvIII in Cancer
  • Toll Like Receptor TLR1:TLR2 Cascade
  • Toll Like Receptor 5 (TLR5) Cascade
  • Gastrin-CREB signalling pathway via PKC and MAPK
  • MyD88 dependent cascade initiated on endosome
  • SOS-mediated signalling
  • Fcgamma receptor (FCGR) dependent phagocytosis
  • SHC-mediated signalling
  • Regulation of actin dynamics for phagocytic cup formation
  • TRIF-mediated TLR3/TLR4 signaling
  • ERK1 activation
  • Senescence-Associated Secretory Phenotype (SASP)
  • ERK1 activation
  • Signaling by VEGF
  • Downstream signal transduction
  • Toll Like Receptor 3 (TLR3) Cascade
  • Signalling to RAS
  • Interleukin-2 signaling
  • Platelet activation, signaling and aggregation
  • Frs2-mediated activation
  • Axon guidance
  • IRS-mediated signalling
  • L1CAM interactions
  • Oncogene Induced Senescence
  • VEGFA-VEGFR2 Pathway
  • Activated TLR4 signalling
  • VEGFR2 mediated cell proliferation
  • GRB2 events in ERBB2 signaling
  • TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
  • MyD88:Mal cascade initiated on plasma membrane
  • NCAM signaling for neurite out-growth
  • RAF/MAP kinase cascade
  • Signalling to p38 via RIT and RIN
  • Innate Immune System
  • Signaling by Insulin receptor
  • ERKs are inactivated
  • Signal transduction by L1
  • Insulin receptor signalling cascade
  • ISG15 antiviral mechanism
  • Interferon Signaling
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • IRS-related events
  • SHC-related events
  • Signaling by FGFR
  • Thrombin signalling through proteinase activated receptors (PARs)
  • ARMS-mediated activation
  • Toll-Like Receptors Cascades
  • Toll Like Receptor 10 (TLR10) Cascade
  • Signal attenuation
  • Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
  • ERK/MAPK targets
  • MAPK targets/ Nuclear events mediated by MAP kinases
  • Signaling by GPCR
  • FCERI mediated MAPK activation
  • SHC1 events in ERBB2 signaling
  • Signaling by SCF-KIT
  • DAP12 signaling
  • Toll Like Receptor 9 (TLR9) Cascade
  • ERK/MAPK targets
  • Negative regulation of FGFR signaling
  • Signaling by PDGF
  • DAP12 interactions
  • SHC-related events triggered by IGF1R
  • GRB2 events in EGFR signaling
  • Signaling by ERBB4
  • Antiviral mechanism by IFN-stimulated genes
  • Toll Like Receptor 2 (TLR2) Cascade
  • Signaling by ERBB2
  • Signaling by EGFR
  • Signaling by Interleukins
  • SHC1 events in ERBB4 signaling
  • Toll Like Receptor 4 (TLR4) Cascade
  • Fc epsilon receptor (FCERI) signaling
  • Signaling by EGFR in Cancer
  • Growth hormone receptor signaling
  • Signaling by Leptin
  • Signalling to ERKs
  • Prolonged ERK activation events
  • ERK activation
  • Toll Like Receptor 7/8 (TLR7/8) Cascade
  • RNA Polymerase I Promoter Clearance
  • IGF1R signaling cascade
  • Toll Like Receptor TLR6:TLR2 Cascade
  • IRS-related events triggered by IGF1R
  • Activation of the AP-1 family of transcription factors
  • MyD88 cascade initiated on plasma membrane
  • ERK activation
  • Downstream signaling of activated FGFR
  • Advanced glycosylation endproduct receptor signaling
  • Signalling by NGF
  • SOS-mediated signalling
  • MAP kinase activation in TLR cascade
  • RNA Polymerase I Transcription
  • SHC-mediated signalling
  • Cytokine Signaling in Immune system
  • Cellular response to heat stress
  • Regulation of HSF1-mediated heat shock response
  • NGF signalling via TRKA from the plasma membrane
  • MyD88-independent cascade
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • SHC1 events in EGFR signaling
  • FRS2-mediated cascade
  • IRS-mediated signalling
  • Oxidative Stress Induced Senescence
  • RNA Polymerase I Promoter Opening
  • Nuclear Events (kinase and transcription factor activation)
  • Sulindac
  • Arsenic trioxide
  • Purvalanol
  • 5-iodotubercidin
DDX5 and PIK3CA DEAD (Asp-Glu-Ala-Asp) box helicase 5 phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha
  • Signaling by the B Cell Receptor (BCR)
  • Signaling by GPCR
  • Metabolism of lipids and lipoproteins
  • Signaling by FGFR in disease
  • Signaling by EGFRvIII in Cancer
  • Signaling by SCF-KIT
  • Downstream signaling events of B Cell Receptor (BCR)
  • DAP12 signaling
  • PI3K/AKT activation
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • Interleukin receptor SHC signaling
  • PI-3K cascade
  • Gastrin-CREB signalling pathway via PKC and MAPK
  • Signaling by FGFR1 mutants
  • Role of phospholipids in phagocytosis
  • Phospholipid metabolism
  • Fcgamma receptor (FCGR) dependent phagocytosis
  • PI3K Cascade
  • Signaling by PDGF
  • DAP12 interactions
  • GAB1 signalosome
  • G-protein beta:gamma signalling
  • CD28 co-stimulation
  • CD28 dependent PI3K/Akt signaling
  • Signaling by ERBB4
  • Constitutive PI3K/AKT Signaling in Cancer
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • PI3K events in ERBB4 signaling
  • G alpha (q) signalling events
  • Signaling by ERBB2
  • Signaling by EGFR
  • GPCR downstream signaling
  • TCR signaling
  • Signaling by Interleukins
  • Signaling by VEGF
  • Downstream signal transduction
  • Signaling by FGFR mutants
  • Fc epsilon receptor (FCERI) signaling
  • Signaling by EGFR in Cancer
  • Nephrin interactions
  • Interleukin-2 signaling
  • PI3K/AKT Signaling in Cancer
  • Platelet activation, signaling and aggregation
  • Interleukin-3, 5 and GM-CSF signaling
  • Adaptive Immune System
  • G alpha (q) signalling events
  • Downstream TCR signaling
  • Costimulation by the CD28 family
  • IRS-mediated signalling
  • PIP3 activates AKT signaling
  • IGF1R signaling cascade
  • VEGFA-VEGFR2 Pathway
  • Synthesis of PIPs at the plasma membrane
  • IRS-related events triggered by IGF1R
  • G beta:gamma signalling through PI3Kgamma
  • PI3K events in ERBB2 signaling
  • Regulation of signaling by CBL
  • Downstream signaling of activated FGFR
  • G alpha (12/13) signalling events
  • PI Metabolism
  • Innate Immune System
  • Signaling by Insulin receptor
  • Signalling by NGF
  • Insulin receptor signalling cascade
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • IRS-related events
  • Cytokine Signaling in Immune system
  • NGF signalling via TRKA from the plasma membrane
  • Tie2 Signaling
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Cell surface interactions at the vascular wall
  • Signaling by FGFR
  • IRS-mediated signalling
  • Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
  • GPVI-mediated activation cascade
  • Interleukin receptor SHC signaling
  • Signaling by FGFR1 fusion mutants
  • Constitutive Signaling by EGFRvIII
  • PI3K Cascade
DLX1 and SMAD4 distal-less homeobox 1 SMAD family member 4
  • Loss of Function of TGFBR2 in Cancer
  • SMAD2/3 MH2 Domain Mutants in Cancer
  • TGF-beta receptor signaling activates SMADs
  • TGFBR1 LBD Mutants in Cancer
  • Downregulation of SMAD2/3:SMAD4 transcriptional activity
  • SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
  • Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer
  • Signaling by BMP
  • Transcriptional regulation of pluripotent stem cells
  • Generic Transcription Pathway
  • Signaling by NODAL
  • TGFBR2 MSI Frameshift Mutants in Cancer
  • SMAD2/3 Phosphorylation Motif Mutants in Cancer
  • Loss of Function of SMAD2/3 in Cancer
  • Signaling by Activin
  • TGFBR2 Kinase Domain Mutants in Cancer
  • Loss of Function of SMAD4 in Cancer
  • TGFBR1 KD Mutants in Cancer
  • Loss of Function of TGFBR1 in Cancer
  • Signaling by TGF-beta Receptor Complex in Cancer
  • Signaling by TGF-beta Receptor Complex
  • SMAD4 MH2 Domain Mutants in Cancer
DNMT3A and MYC DNA (cytosine-5-)-methyltransferase 3 alpha v-myc avian myelocytomatosis viral oncogene homolog
  • Chromatin modifying enzymes
  • Chromatin organization
  • Epigenetic regulation of gene expression
  • PRC2 methylates histones and DNA
  • RMTs methylate histone arginines
  • DNA methylation
  • Loss of Function of TGFBR2 in Cancer
  • Signaling by NOTCH1 HD Domain Mutants in Cancer
  • Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer
  • SMAD2/3 MH2 Domain Mutants in Cancer
  • Signaling by Wnt
  • Cyclin E associated events during G1/S transition
  • binding of TCF/LEF:CTNNB1 to target gene promoters
  • TGFBR1 LBD Mutants in Cancer
  • SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
  • Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer
  • Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant
  • Generic Transcription Pathway
  • RNF mutants show enhanced WNT signaling and proliferation
  • G1/S Transition
  • Signaling by NOTCH1
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • Signaling by NOTCH1 in Cancer
  • Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
  • Mitotic G1-G1/S phases
  • FBXW7 Mutants and NOTCH1 in Cancer
  • TGFBR2 MSI Frameshift Mutants in Cancer
  • SMAD2/3 Phosphorylation Motif Mutants in Cancer
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • Loss of Function of SMAD2/3 in Cancer
  • Signaling by NOTCH
  • formation of the beta-catenin:TCF transactivating complex
  • TGFBR2 Kinase Domain Mutants in Cancer
  • Loss of Function of SMAD4 in Cancer
  • TGFBR1 KD Mutants in Cancer
  • S Phase
  • Cell Cycle, Mitotic
  • Loss of Function of TGFBR1 in Cancer
  • NOTCH1 Intracellular Domain Regulates Transcription
  • Signaling by TGF-beta Receptor Complex in Cancer
  • Signaling by TGF-beta Receptor Complex
  • TCF dependent signaling in response to WNT
  • Signaling by NOTCH1 PEST Domain Mutants in Cancer
  • Cyclin A:Cdk2-associated events at S phase entry
  • Signaling by WNT in cancer
  • Constitutive Signaling by NOTCH1 PEST Domain Mutants
  • SMAD4 MH2 Domain Mutants in Cancer
HBEGF and EGFR heparin-binding EGF-like growth factor epidermal growth factor receptor
  • Signaling by the B Cell Receptor (BCR)
  • Signaling by GPCR
  • Signaling by FGFR in disease
  • PIP3 activates AKT signaling
  • Signaling by EGFRvIII in Cancer
  • Signaling by SCF-KIT
  • SHC1 events in ERBB2 signaling
  • Downstream signaling events of B Cell Receptor (BCR)
  • DAP12 signaling
  • EGFR Transactivation by Gastrin
  • PI3K/AKT activation
  • Uptake and actions of bacterial toxins
  • PI-3K cascade
  • GRB2 events in ERBB2 signaling
  • Gastrin-CREB signalling pathway via PKC and MAPK
  • PI3K events in ERBB2 signaling
  • Downstream signaling of activated FGFR
  • Innate Immune System
  • Signaling by PDGF
  • Signalling by NGF
  • DAP12 interactions
  • GAB1 signalosome
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • NGF signalling via TRKA from the plasma membrane
  • Signaling by ERBB4
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • Constitutive PI3K/AKT Signaling in Cancer
  • PI3K events in ERBB4 signaling
  • Signaling by FGFR
  • Signaling by ERBB2
  • Signaling by EGFR
  • Nuclear signaling by ERBB4
  • SHC1 events in ERBB4 signaling
  • Downstream signal transduction
  • Fc epsilon receptor (FCERI) signaling
  • Signaling by EGFR in Cancer
  • PI3K/AKT Signaling in Cancer
  • Adaptive Immune System
  • Uptake and function of diphtheria toxin
  • Signaling by the B Cell Receptor (BCR)
  • Signaling by GPCR
  • Signaling by FGFR in disease
  • Signaling by EGFRvIII in Cancer
  • PLCG1 events in ERBB2 signaling
  • SHC1 events in ERBB2 signaling
  • Signaling by SCF-KIT
  • DAP12 signaling
  • Downstream signaling events of B Cell Receptor (BCR)
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • PI3K/AKT activation
  • PI-3K cascade
  • Gastrin-CREB signalling pathway via PKC and MAPK
  • Signaling by PDGF
  • EGFR downregulation
  • DAP12 interactions
  • GAB1 signalosome
  • GRB2 events in EGFR signaling
  • Signaling by ERBB4
  • Constitutive PI3K/AKT Signaling in Cancer
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • PI3K events in ERBB4 signaling
  • EGFR interacts with phospholipase C-gamma
  • Signaling by ERBB2
  • Signaling by EGFR
  • Downstream signal transduction
  • Signaling by EGFR in Cancer
  • Fc epsilon receptor (FCERI) signaling
  • PI3K/AKT Signaling in Cancer
  • Adaptive Immune System
  • Axon guidance
  • PIP3 activates AKT signaling
  • L1CAM interactions
  • EGFR Transactivation by Gastrin
  • GRB2 events in ERBB2 signaling
  • PI3K events in ERBB2 signaling
  • Downstream signaling of activated FGFR
  • Innate Immune System
  • Signalling by NGF
  • Signal transduction by L1
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • NGF signalling via TRKA from the plasma membrane
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Inhibition of Signaling by Overexpressed EGFR
  • Signaling by FGFR
  • SHC1 events in EGFR signaling
  • Constitutive Signaling by EGFRvIII
  • Cetuximab
  • Trastuzumab
  • Lidocaine
  • Gefitinib
  • Erlotinib
  • Lapatinib
  • Panitumumab
  • Flavopiridol
  • Vandetanib
  • S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE
  • N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE
  • Afatinib
DVL1 and CCDC88C dishevelled segment polarity protein 1 coiled-coil domain containing 88C
  • disassembly of the destruction complex and recruitment of AXIN to the membrane
  • WNT mediated activation of DVL
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • TCF dependent signaling in response to WNT
  • RNF mutants show enhanced WNT signaling and proliferation
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • degradation of DVL
  • negative regulation of TCF-dependent signaling by DVL-interacting proteins
  • Signaling by Wnt
  • Signaling by WNT in cancer
  • PCP/CE pathway
  • beta-catenin independent WNT signaling
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • TCF dependent signaling in response to WNT
  • RNF mutants show enhanced WNT signaling and proliferation
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • Signaling by Wnt
  • negative regulation of TCF-dependent signaling by DVL-interacting proteins
  • Signaling by WNT in cancer

Page 36 out of 1171 pages